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Abstract
Tumour-associated Macrophages (TAM) present two different polarizations: classical (M1) characterized by immunostimulation activity and
tumour suppression; alternative (M2) characterized by tumour promotion and immune suppression. In this retrospective study, we evaluated
the correlation between the two forms of TAM with survival time in radically resected gastric cancer patients. A total of 52 chemo- and radio-
naive patients were included. Two slides were prepared for each patient and double-stained for CD68/NOS2 (M1) or CD68/CD163 (M2) and
five representative high-power fields per slide were evaluated for TAM count. The median value of the two macrophage populations density
and the median value of M1/M2 ratio were used as cut-off. Twenty-seven patients with M1 density above-the-median had a significantly higher
survival compared to those below the median. Twenty-six patients with M1/M2 ratio above the median showed median OS of 27.2 months
compared to 15.5 months of the patients below the median. No association between M2 macrophage density and patient’s outcome was
found. In multivariate analysis, M1/M2 was a positive independent predictor of survival. The M1 macrophage density and M1/M2 ratio, as con-
firmed in multivariate analysis, are factors that can help in predicting patients survival time after radical surgery for gastric cancer.
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Introduction
Tumour-associated macrophages (TAMs) represent a substantial
fraction of the growing tumour mass and are associated with poor
prognosis in several human cancers [1]. TAMs exist in two different
polarizations classified as M1 and M2. M1 macrophages show a pro-
tective role in tumorigenesis activating tumour-killing mechanisms
and antagonizing the activities of different M2 macrophages that are
clearly involved in suppression of adaptive tumour-specific immune
responses and in promotion of tumour growth, invasion, metastasis,
stroma remodelling and angiogenesis [2–6]. Unfortunately, the
majority of TAM exhibit characteristics of M2 polarization [7, 8]. M1
macrophages differentiation is induced by interferon-c, lipopolysac-
charides, tumour necrosis factor (TNFa) and granulocyte–monocyte
colony-stimulating factor and are phenotypically characterized by high
levels of interleukin IL-12, IL-23, TNFa, IL-1, IL-6, granulocyte-–mac-
rophage colony-stimulating factor (GM-CSF), CXC ligand 10 (CXCL10),
inducible nitric oxide synthase (iNOS), human leucocyte antigen
(HLA)-DR, reactive oxygen and nitrogen intermediates. M2 macro-
phages differentiation is induced by IL-4, IL-10, IL-13, IL-21, activin A,
immune complexes, and glucocorticoid and express high levels of
IL-10, IL-1 receptor antagonist, CC ligand 22 (CCL22), scavenger, man-
nose and galactose receptors, arginase I and CD163 antigen [7, 9–14].
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Specifically, it has been reported that TAM infiltration into tumour
tissue correlates significantly with tumour vascularity in human
oesophageal and gastric cancers [15] and it is also has been found a
direct association between the degree of TAM infiltration and depth of
tumour invasion, nodal status and clinical stage in gastric cancer
[16]. Nevertheless, no study evaluated the correlation between M1/
M2 tumour infiltration and the overall survival (OS) in gastric cancer
patients. Against these backgrounds, we have decided to evaluate the
prognostic role of TAM infiltration in patients affected by radically
resected gastric cancer.
Materials and methods
Study population
This study was approved by the Institutional Review Board of Campus
Bio-Medico University, Rome, Italy. The procedures to obtain human gas-
tric cancer tissues and follow-up information are in accordance with the
Ethical Principles for Medical Research Involving Human Subjects as for-
mulated in the World Medical Association Declaration of Helsinki (revised
in 2008). All specimens were retrospectively obtained from the archives
of formalin-fixed, paraffin-embedded tissue blocks in the Departments of
pathology of Campus Bio-Medico University, Rome, and of Medical Uni-
versity of Pesaro-Urbino, Italy. The gastric cancer tissues were collected
from surgeries performed from May 2000 to August 2004. The patients
were followed up until December 2011 through outpatient visits and/or
correspondences to family members. The inclusion criteria were com-
plete follow-up data, paraffin blocks available, R0 radical surgery, pre-
operative chemotherapy or radiotherapy excluded. All of the cases that
satisfied the inclusion criteria were included in this study. The patients
were selected without knowledge of their previous tumour macrophage
counts. Histological evaluation was based on the World Health Organiza-
tion criteria [17]. Pathological findings (tumour size, spread and lymph-
node status) were obtained from the pathologist’s original reports.
Tumour–node–metastasis status (TNM) classification was reassessed
using seventh edition of the UICC/AJCC classification [18].
Statistical analysis
The OS time was calculated as the period from the date of surgery until
death. OS was determined by Kaplan–Meier product-limit method.
Moreover, the differences in terms of OS according to the prognostic
variables were evaluated by the log-rank test. Finally, the Cox propor-
tional hazards model was applied to the multivariate survival analysis
[19]. SPSS software (version 19.00, SPSS, Chicago, IL, USA) was used
for statistical analysis. A P value of less than 0.05 was considered to
indicate statistical significance.
Immunofluorescence
The gastric cancer tissue specimens of 52 patients who had undergone
resection for curative intent were analysed. All sections contained tumour
and peritumoural tissue. Consecutive 3 lm sections were cut from each
block for immunofluorescence experiments. To evaluate M1 and M2
macrophages population, mouse anti-human macrophage CD68 mAb
(dilution 1:50; clone PG-M1, DAKO, Hamburg, Germany), CD163 rabbit
monoclonal mAb (dilution1:200; clone 10D6, Novocastra, Newcastle upon
Tyne, UK) and NOS2 rabbit polyclonal antibody (N-20) (dilution 1:400;
Santa Cruz Biotecnology Inc., Santa Cruz, CA, USA) were adopted. Incu-
bation with primary antibodies against CD68 was followed by Alexa Fluor
488 (dilution 1:200; goat antimouse; Invitrogen, USA); NOS2 and CD163
was followed by and Alexa Fluor 568 (dilution 1:200; donkey anti-rabbit
Invitrogen, Darmstadt, Germany). A mounting medium containing DAPI
(Vectashield, Vector Laboratories, Burlingame, CA, USA) was used. Nega-
tive control slides processed without primary antibodies were included
for each staining. Thus, two slides were prepared for each patient and
double-staining of CD68/NOS2 (markers for M1 macrophages) and CD68/
CD163 (markers for M2 macrophages) was performed.
Analysis and validation of immunostaining
Five representative high-power fields (9400 magnification) of the deepest
infiltrative tumour areas per tissue section were selected using an Eclipse
80i Nikon microscope (Nikon, Tokyo, Japan). Acquisition was carried out
using the Imaging Software NIS-Elements (Nikon). Cell counts were per-
formed on collected composite images, in which the signal from the fluo-
rochrome had been assigned a different pseudo-colour (green for 488,
red for 568 and blue for DAPI). Adobe Photoshop CS 5 (version 5.5) soft-
ware was used to generate composite images from three different fluoro-
chrome signals. The number of nucleated cells with positive staining for
the phenotype marker in each image was then counted manually. Evalua-
tion was performed simultaneously by two investigators (MA, PB) who
were blinded as regards which group the specimens belonged to and to
patient outcome. The investigators analysed M1 macrophages, M2 mac-
rophages and the M1/M2 ratio counting the absolute macrophage num-
ber for all high-power field per section (Fig. 1).
Results
Patient characteristics
Fifty-two patients were included in this retrospective study. All of the
patients had complete follow-up information and the pathological
diagnosis was confirmed by a pathologist prior to inclusion in this
study. No patients received chemotherapy and/or radiotherapy before
or after surgery. The overall cumulative survival rates were 77% (40
patients) for 1 year, 42% (22) for 2 years, 15% (8) for 3 years, 13%
(7) for 4 years and 11% (6) for 5 years. The clinicopathological char-
acteristics were summarized in Table 1.
Macrophage distribution
In the five representative high-power fields (9400 magnification) per
tissue section of the 52 patients, the median cell count value of CD68/
NOS2 macrophages (markers for M1 polarization) was 7.0 (mean
7.4  3.4; CI: 6.5–8.3) whereas the median cell count value of CD68/
CD163 (markers for M2 polarization) was 6.4 (mean 7  3.9; CI:
5.9–8.1). In addition, M1/M2 ratio was calculated. The median value
1416 ª 2013 The Authors.
Journal of Cellular and Molecular Medicine Published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
of M1/M2 ratio between the median cell count value of the two mac-
rophage populations was 1.16 (mean 1.26  0.70; CI: 1.07–1.45).
Correlation between the M1/M2 macrophage
density and the M1/M2 ratio with
clinicopathological characteristics
We found that there was no statistically significant association
between the M1 macrophage density, M2 macrophage density and
M1/M2 ratio with clinicopathological characteristics as tumour stage,
histology, lymphonode invasion and grade (P > 0.05).
Correlation between the M1/M2 macrophage
density and the M1/M2 ratio with survival time
To assess whether there is any value of the macrophage density of
M1 and M2 in predicting prognosis, the median value of the macro-
phage density of two populations was used as a cut-off point to
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Fig. 1 Immunohistochemistry of macro-
phage in gastric cancer. Gastric cancer
stained for M1 (A–C) and M2 (E–G)
immunofluorescence pattern. (A, E) Nucle-
ated cells positive staining for CD68
(green), which resulted in cytoplasm
staining of macrophages. (B) INOS stain-
ing (red) in some nucleated cells. (C)
Merged image of DAPI (blue), CD68
(green) and INOS (red) defining M1 mac-
rophages (green/red double staining). (F)
CD163 staining (red) in nucleated cells.
(G) Merged image of DAPI (blue), CD68
(green) and CD163 (red) defining M2
macrophages (green/red double staining).
(D, H) E&E images of immunofluores-
cence fields. Original magnification 4009.
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dichotomize the 52 patients into a group with a macrophage density
above or below the median value according to previous studies [20,
21]. Kaplan–Meier survival curves were plotted to investigate further
the association of cell densities with survival. The log-rank test was
used to compare survival rates. We found that the 27 patients with
above-the-median M1 macrophage density had a 1-year survival rate
of 81% (22 patients), 2-year survival rate of 55% (15), 3-year survival
rate of 26% (7), 4-year survival rate of 22% (6) and 5-year survival
rate of 18% (5) with median survival of 25.6 months, which were sig-
nificantly higher than the corresponding survival rates 72% (18),
24% (6), 4% (1), 4% (1) and 4% (1) with Median Survival of
17.1 months, respectively, in the 25 patients with below-the-median
M1 macrophage density, with P = 0.041 (P < 0.05) (Fig. 2, Table 2).
In contrast, the 27 patients with above-the-median M2 macrophage
density had a 1-year survival rate of 70% (19), 2-year survival rate of
37% (10), 3-year survival rate of 15% (4), 4-year survival rate of 11%
(3) and 5-year survival rate of 11% (3) with median survival of
17.6 months, which were lower but not significantly than the corre-
sponding survival rates 84% (21), 48% (12), 16% (4), 16% (4) and
12% (3) with median survival of 22.3 months, respectively, in the 25
patients with below-the-median M2 macrophage density, with
P = 0.724 (P > 0.05) (Fig. 3). The median value of the M1/M2 ratio
was used as a cut-off point to dichotomize the 52 patients into a
group with a M1/M2 ratio above or below the median. The 26 patients
with above-the-median M1/M2 ratio had a 1-year survival rate of 88%
(23), 2-year survival rate of 65% (17), 3-year survival rate of 27%(7),
4-year survival rate of 23% (6) and 5-year survival rate of 15% (4)
with median survival of 27.2 months, which were significantly higher
compared with the corresponding survival rates of 65% (17), 19%
(5), 3% (1), 3% (1) and 3% (1), respectively, in the 26 patients with
below-the-median M1/M2 ratio with Median Survival of 15.5 months
with P = 0.001 (P < 0.05)(Fig. 4, Table 2). To determine whether the
macrophage density is independently associated with patient’s sur-
vival time, the multivariate Cox proportional hazards analysis was
used. Extent of the tumour (T), spread to regional lymph nodes (N)
and differentiation grade (G) were included in the multivariate analysis
along with macrophage density M1 and the M1/M2 ratio. In the multi-
variate analysis, we found that only the M1/M2 ratio was a positive
independent predictor of patient’s survival time (P = 0.001; hazard
ratio 0.410) (Table 2). The M1 macrophage densities had no statisti-
cally significant association with patient’s survival time in the multi-
variate analysis (P > 0.05).
Discussion
Macrophages are one of the major populations of tumour-infiltrating
immune cells. In most of the solid tumours, however, the existence of
TAM is advantageous for tumour growth and metastasis [1]. It is
demonstrated that tumour escape has been linked with a switch from
M1 activation in the early tumour initiation process towards M2-like
phenotype during tumour progression [22]. M1 and M2 subsets differ
in terms of phenotype and functions. M1 cells have high microbicidal
activity, immuno-stimulatory functions and tumour cytotoxicity. On
the other hand, M2 cells produce interleukin 10 (IL-10) and
Table 1 Clinicopathological characteristics (n = 52)
Median survival (months; Mean  SD) 21.5 (27.45  25.56)
Age (years; Mean  SD) 61.7  1.2
Gender (male:female) 23:29
Tumour stage, number (%)
Ia 1 (2)
Ib 3 (5)
IIa 18 (34)
IIb 9 (17)
IIIa 9 (17)
IIIb 12 (23)
Histology, number (%)
Intestinal 29 (55)
Diffuse 10 (19)
Mix 9 (17)
Poorly differentiated 4 (7)
Tumour grade, number (%)
G1 5 (9)
G2 17 (33)
G3 28 (54)
Not recorded 2 (4)
Fig. 2 Kaplan–Meier 5-year survival curves according to M1 polariza-
tion.
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transforming growth factor b (TGF- b) leading to a suppression of
general antitumour immune responses, promoting tumour neoangio-
genesis by the secretion of pro-angiogenic factors and defining the
invasive microenvironment to facilitate tumour metastasis and dis-
semination [23]. Anyway, at present, there is conflicting evidence
regarding the role of tumour macrophage infiltrate in influencing
patients survival. In many human neoplasms including lung, breast,
cervix, bladder, ovary and pancreas cancers, the presence of exten-
sive TAM infiltrate correlates with poor prognosis. In other tumours,
including those of the brain and prostate, there is conflicting evidence
regarding the role of macrophages in survival outcome [1, 24–27].
The basis for these conflicting data may be explained considering that
in these studies tumour-associated macrophages were detected only
by the immunohistochemical analysis of CD68+ cells. Matter of fact,
CD68 expression is shared between M1 and M2 phenotypes and theT
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use of CD68 as sole could not represent a reliable marker in evaluat-
ing the real impact of the two subtypes with almost opposite biologi-
cal properties. Only two studies have analysed the relationship
between M1 and M2 macrophages and prognosis using a double IHC
staining to better characterize the two subsets of TAM. These reports
demonstrated a significant direct correlation between M1 phenotype
infiltrate and the survival time of patients affected by non-small cells
lung cancer (NSCLC) [20, 21]. In our study, we used double-staining
for CD68/NOS2 as markers for M1 macrophages and CD68/CD163 as
markers for M2 macrophages to be in accordance with the most part
of previously published studies that performed a phenotypic charac-
terization of macrophages polarization [20, 25, 28–34]. The haemo-
globin scavenger receptor, CD163, is expressed on tissue
macrophages and monocytes after M2 polarization [35]. Conversely,
macrophages M1 polarized by exposure to interferon (IFN)-c or LPS
up-regulate inducible nitric oxide synthase (iNOS) to convert into
nitric oxide that combining with oxygen radicals lead to the formation
of cytotoxic peroxynitrite [36]. These markers are not absolutely spe-
cific, for example CD68 has been found in immature CD1a-positive
dendritic cells [37, 38], CD163 is also expressed in some dendritic
cells [39], and iNOS is expressed by endothelial cells [40] as well as
by arterial wall smooth muscle cells [41]. For these reasons, we paid
particular attention to cell morphology to minimize these potential
bias: in this direction we used DAPI as nuclear morphological marker
and we counted as positive merely nucleate cell avoiding possibility
to count the same cell more than once.
At present, gastric cancer has poor overall survival at 5 years.
The therapeutic approach is multidisciplinary and the surgery plays a
central role [42], even if the overall survival after radical surgery
remains poor. Only 29% of patients undergoing a D2 linfectomy and
21% of those undergoing a D1 linfectomy are alive at 15 years from
surgery. Moreover, radical surgery in gastric cancer is often associ-
ated with important comorbidities [43]. The discovery of new and reli-
able bio-markers able to select patients who really benefit from
surgery is an urgent need in clinical practice.
Currently, the only proven prognostic indicators are represented
by clinical-pathological factors such as age, sex, gastric wall infiltra-
tion, locoregional nodal involvement, Laurens’ histology and margins.
Furthermore, in the last years, a growing attention was paid to new
molecular prognostic markers related to cancer cell biology while few
data are available about the role of tumour microenvironment in pre-
dicting patient’s outcome. Two recent works demonstrated that gas-
tric cancer patients with an high TAM count showed poorer surgical
outcome than those with a low TAM count [16, 44]. On the contrary,
this is the first study investigating the two forms of macrophages
population in gastric cancer. We demonstrated that the M1 macro-
phage density is a prognostic factor in univariate analysis in accor-
dance with previous reports on the association of M1-survival time in
patients affected by non-small cells lung cancer [20, 21]. More inter-
estingly, in our experience, only the M1/M2 ratio was an independent
prognostic factor. Therefore, the cellular and molecular interactions
between M1 and M2 population appear to play a major role in deter-
mining prognosis of gastric cancer patients. These data support
future larger prospective confirming studies investigating the prog-
nostic role of TAM polarization in radically resected gastric cancer
with the aim to discriminate patients who could take the most advan-
tage from surgery. Finally, these results highlight new therapeutic
horizons involving strategies aiming to reverse TAM phenotype in
gastric cancer.
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